Related Experiment Video
Updated: May 14, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Familial LCAT deficiency: from renal replacement to enzyme replacement
R M Stoekenbroek1, M A van den Bergh Weerman, G K Hovingh
1Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.
Abstract:
Familial LCAT deficiency (FLD) is a recessive lipid disorder ultimately leading to end-stage renal disease (ESRD). We present two brothers with considerable variation in the age at which they developed ESRD. Kidney biopsies revealed both tubular and glomerular pathology. To date, no causal therapy is available, yet enzyme replacement therapy is in development.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy
Chronic Kidney Disease III: Interprofessional Care
Kidney Transplant I: Introduction
Lysosomal Hydrolases

